Sugarbaker, P. H., & Van der Speeten, K. (2021). Peritoneal progression after pancreaticoduodenectomy is a devastating surgical treatment failure: HIPEC gemcitabine is an option. J Gastrointest Oncol.
Chicago Style CitationSugarbaker, Paul H., i Kurt Van der Speeten. "Peritoneal Progression After Pancreaticoduodenectomy Is a Devastating Surgical Treatment Failure: HIPEC Gemcitabine Is an Option." J Gastrointest Oncol 2021.
Cita MLASugarbaker, Paul H., i Kurt Van der Speeten. "Peritoneal Progression After Pancreaticoduodenectomy Is a Devastating Surgical Treatment Failure: HIPEC Gemcitabine Is an Option." J Gastrointest Oncol 2021.
Atenció: Aquestes cites poden no estar 100% correctes.